Walleye Capital’s Myriad Genetics MYGN Stock Holding History

Walleye Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4K	Buy	+700	New	+$3.18K	﹤0.01%	4553
2025 Q4	–	Sell	-100	Closed	-$723	–	4945
2025 Q3	$723	Buy	+100	New	+$594	﹤0.01%	4384
2024 Q1	–	Sell	-1,000	Closed	-$19.1K	–	5721
2023 Q4	$19.1K	Sell	1,000 -2,000	-67%	-$34.6K	﹤0.01%	4480
2023 Q3	$48.1K	Buy	+3,000	New	+$57.1K	﹤0.01%	4200
2020 Q1	–	Sell	-2,300	Closed	-$63K	–	1414
2019 Q4	$63K	Sell	2,300 -5,500	-71%	-$151K	﹤0.01%	1475
2019 Q3	$223K	Buy	+7,800	New	+$227K	0.01%	1149
2019 Q2	–	Sell	-2,000	Closed	-$66K	–	1932
2019 Q1	$66K	Buy	+2,000	New	+$60.9K	0.01%	1149

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Capital's MYGN Position: Q2 2026 in Review

Walleye Capital opened a new position in Myriad Genetics (MYGN) in Q2 2026: 464,647 shares worth $2.65M. The stake represents 0.01% of the portfolio and ranks #1288 among its holdings. This is a return to the name: Walleye Capital previously reported a position in MYGN as recently as Q4 2025.

Walleye Capital first reported a position in MYGN in Q1 2019 and has held it in 18 quarters since. The position peaked at $4.16M in Q4 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Walleye Capital held 464,647 shares of Myriad Genetics worth $2.65M as of Q2 2026.
Myriad Genetics was a new Walleye Capital position in Q2 2026.
Myriad Genetics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1288 holding.
Walleye Capital first reported a position in Myriad Genetics in Q1 2019 and has held it in 18 quarters since.
Walleye Capital's Myriad Genetics position peaked at $4.16M in Q4 2025.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.